This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat Likely for F5 Networks (FFIV) This Earnings Season?
by Zacks Equity Research
F5 Networks' (FFIV) Q3 performance is likely to have benefited from the hybrid work environment and the ongoing digital transformation wave, which is boosting the demand for secured communication networks.
Merck's (MRK) Keytruda Head and Neck Cancer Study Fails
by Zacks Equity Research
Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.
Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.
LabCorp (LH) to Offer New Test Report for Venom Allergy Testing
by Zacks Equity Research
LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
What's in the Offing for Infosys (INFY) This Earnings Season?
by Zacks Equity Research
The strong demand for the cloud, data analytics, the Internet of Things and security products and solutions amid the ongoing digital transformation wave is likely to have boosted Infosys' (INFY) Q1 performance.
Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to benefit from better patient volumes. The results might partly suffer from escalating labor costs that might dampen bottom line growth.
GSK Completes Demerger of Consumer Healthcare Business
by Zacks Equity Research
Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.
Company News for Jul 19, 2022
by Zacks Equity Research
Companies in The News Are: SYF,DAL,BA,SGEN,MRK,SBUX
J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.
Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood
by Sejuti Banerjea
JNJ Management expects relatively consistent growth for the rest of the year.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Strong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
by Zacks Equity Research
Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.
AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
by Zacks Equity Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
Merck and Block have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Merck and Block have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Merck & Co. (MRK)
by Benjamin Rains
Merck & Co. (MRK) is a $240 billion market cap pharmaceutical titan that's climbed over 20% in 2022. The firm is continuing to make acquisitions and many of Merck's fundamentals make it an attractive play for the second half of 2022
UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.
Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M
by Zacks Equity Research
Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.